Evotec, Harvard, J&J Combine in Preclinical Diabetes Alliance
By Cormac Sheridan
Wednesday, July 11, 2012
CureBeta, the diabetes research alliance between Evotec AG and Doug Melton's lab in Harvard University's Department of Stem Cell and Regenerative Biology, has found an early taker for its preclinical portfolio of small molecules and biologics that can trigger growth of insulin-secreting pancreatic beta cells.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.